BioCentury | Jun 26, 2020
Management Tracks

Saunders joins BridgeBio’s board; plus changes at BioXcel, FibroGen, Storm, Athenex, Seres, Chimerix and Catalyst

Brent Saunders has joined the the board of BridgeBio Pharma Inc. (NASDAQ:BBIO); he was chairman, president and CEO of Allergan plc in 2015-20 until its takeout by AbbVie Inc. (NYSE:ABBV) in May. The genetic diseases...
BioCentury | Jun 22, 2020
Emerging Company Profile

Prosit Sole: chimeric proteins for rare disease

Prosit Sole is improving upon protein and cytokine therapies against validated targets for rare diseases using its chimeric protein engineering platform. The idea is to combine desirable structural features from different protein family members to...
BioCentury | May 28, 2020
Management Tracks

Quick departure for Semerjian as Immunomedics CEO; plus Ziopharm, Kinnate, Applied Therapeutics, Relmada, AskBio and more

Less than two months after becoming president and CEO of Immunomedics Inc. (NASDAQ:IMMU), Harout Semerjian is stepping down because of “unfortunate significant logistical obstacles presented by the COVID-19 pandemic,” according to the cancer company. Executive...
BioCentury | Apr 29, 2020
Product Development

April 28 Quick Takes: Syndax gains on leukemia data; plus Supernus, Neurocrine, Avadel, Insilico-Astellas, Innovent-Lilly, Chimerix

AACR data propel Syndax shares Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) rose $7.99 (69%) to $19.50 on Tuesday after presenting initial data from the Phase I/II AUGMENT-101 trial of SNDX-5613 that showed responses in two out of...
BioCentury | May 9, 2019
Company News

May 9 Company Quick Takes: Chimerix, Puma, Janssen

Chimerix abandons brincidofovir trials Chimerix Inc. (NASDAQ:CMRX) will cut its workforce in half after deciding to discontinue all clinical trials of adenovirus candidate brincidofovir due to low patient recruitment, five years after access to the...
BioCentury | Apr 9, 2019
Company News

Management tracks: Cyclerion, Alkermes, Alder

A week after completing its spinout from Ironwood, Cyclerion has hired Andreas Busch as chief innovation officer. Busch was EVP, head of R&D and CSO at Shire plc and previously served as EVP, head of...
BioCentury | Feb 6, 2019
Company News

Management tracks: Astellas, Blueprint

Astellas Pharma Inc. (Tokyo:4503) said President of Pharmaceutical Technology Mitsunori Matsuda and President of Asia & Oceania Business Masatoshi Kuroda will resign, effective June 18. Hideki Shima will succeed Matsuda. Cancer and rare diseases company...
BioCentury | Dec 15, 2018
Regulation

FDA to facilitate access to unapproved drugs

FDA plans to launch a new program in 2019 that will help patients gain access to unapproved therapies. The agency will field telephone requests from physicians and patients, streamline the application process, and act as...
BioCentury | Apr 28, 2017
Clinical News

Tenofovir exalidex: Interim Ph IIa data

Interim data from 12 treatment-naïve patients with HBV infection in an open-label, Thai Phase IIa trial showed that once-daily 100 mg oral tenofovir exalidex led to a lower mean HBV viral load after 21 days...
BioCentury | Feb 28, 2017
Clinical News

Merck CMV prophylaxis headed for U.S., EU submissions

Merck & Co. Inc. (NYSE:MRK) said it will submit applications in the U.S. and EU this year for letermovir (MK-8228) to prevent cytomegalovirus (CMV) infection in CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplantation...
Items per page:
1 - 10 of 176
BioCentury | Jun 26, 2020
Management Tracks

Saunders joins BridgeBio’s board; plus changes at BioXcel, FibroGen, Storm, Athenex, Seres, Chimerix and Catalyst

Brent Saunders has joined the the board of BridgeBio Pharma Inc. (NASDAQ:BBIO); he was chairman, president and CEO of Allergan plc in 2015-20 until its takeout by AbbVie Inc. (NYSE:ABBV) in May. The genetic diseases...
BioCentury | Jun 22, 2020
Emerging Company Profile

Prosit Sole: chimeric proteins for rare disease

Prosit Sole is improving upon protein and cytokine therapies against validated targets for rare diseases using its chimeric protein engineering platform. The idea is to combine desirable structural features from different protein family members to...
BioCentury | May 28, 2020
Management Tracks

Quick departure for Semerjian as Immunomedics CEO; plus Ziopharm, Kinnate, Applied Therapeutics, Relmada, AskBio and more

Less than two months after becoming president and CEO of Immunomedics Inc. (NASDAQ:IMMU), Harout Semerjian is stepping down because of “unfortunate significant logistical obstacles presented by the COVID-19 pandemic,” according to the cancer company. Executive...
BioCentury | Apr 29, 2020
Product Development

April 28 Quick Takes: Syndax gains on leukemia data; plus Supernus, Neurocrine, Avadel, Insilico-Astellas, Innovent-Lilly, Chimerix

AACR data propel Syndax shares Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) rose $7.99 (69%) to $19.50 on Tuesday after presenting initial data from the Phase I/II AUGMENT-101 trial of SNDX-5613 that showed responses in two out of...
BioCentury | May 9, 2019
Company News

May 9 Company Quick Takes: Chimerix, Puma, Janssen

Chimerix abandons brincidofovir trials Chimerix Inc. (NASDAQ:CMRX) will cut its workforce in half after deciding to discontinue all clinical trials of adenovirus candidate brincidofovir due to low patient recruitment, five years after access to the...
BioCentury | Apr 9, 2019
Company News

Management tracks: Cyclerion, Alkermes, Alder

A week after completing its spinout from Ironwood, Cyclerion has hired Andreas Busch as chief innovation officer. Busch was EVP, head of R&D and CSO at Shire plc and previously served as EVP, head of...
BioCentury | Feb 6, 2019
Company News

Management tracks: Astellas, Blueprint

Astellas Pharma Inc. (Tokyo:4503) said President of Pharmaceutical Technology Mitsunori Matsuda and President of Asia & Oceania Business Masatoshi Kuroda will resign, effective June 18. Hideki Shima will succeed Matsuda. Cancer and rare diseases company...
BioCentury | Dec 15, 2018
Regulation

FDA to facilitate access to unapproved drugs

FDA plans to launch a new program in 2019 that will help patients gain access to unapproved therapies. The agency will field telephone requests from physicians and patients, streamline the application process, and act as...
BioCentury | Apr 28, 2017
Clinical News

Tenofovir exalidex: Interim Ph IIa data

Interim data from 12 treatment-naïve patients with HBV infection in an open-label, Thai Phase IIa trial showed that once-daily 100 mg oral tenofovir exalidex led to a lower mean HBV viral load after 21 days...
BioCentury | Feb 28, 2017
Clinical News

Merck CMV prophylaxis headed for U.S., EU submissions

Merck & Co. Inc. (NYSE:MRK) said it will submit applications in the U.S. and EU this year for letermovir (MK-8228) to prevent cytomegalovirus (CMV) infection in CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplantation...
Items per page:
1 - 10 of 176